Homocisteína e risco cardiovascular

Autores/as

  • Wagner de Jesus Pinto Pontifícia Universidade Católica de Campinas
  • Miguel Arcanjo Areas Pontifícia Universidade Católica de Campinas
  • José Eduardo de Marialva Pontifícia Universidade Católica de Campinas
  • Silvana Maria Guida Cardoso Pontifícia Universidade Católica de Campinas
  • Elisabete Graisfimberg Pinto Pontifícia Universidade Católica de Campinas

Palabras clave:

Aterosclerose, Doenças cardiovasculares, Hiper-homocisteinemia, Homocisteín, Óxido nítrico

Resumen

Numerosos estudos epidemiológicos têm demonstrado que a hiper-homocisteinemia é um forte e independente fator de risco para o desenvolvimento da doença vascular. A hiper-homocisteinemia pode ser decorrente da deficiência de enzimas envolvidas no metabolismo desse aminoácido ou de seus cofatores  (vitaminas). Várias hipóteses têm sido propostas para explicar o mecanismo celular que envolve a hiper-homocisteinemia e a doença vascular, como o estresse oxidativo. Os fatores de risco convencionais para doenças vasculares, como a aterosclerose, incluem hipercolesterolemia, hipertensão arterial, diabetes mellitus e tabagismo, que respondem por aproximadamente 50% dos casos. Evidências indicam atualmente que a hiper-homocisteinemia ocorre em aproximadamente 5% a 7% da população em geral e que é um importante fator de risco independente para o desenvolvimento da aterosclerose. No Brasil, a doença vascular é responsável por mais de 300 mil mortes por ano e corresponde a 16% dos gastos do Sistema Único de Saúde. Contudo mais de 40% dos pacientes diagnosticados com doença coronária prematura, vascular periférica ou trombose venosa recorrente apresentam hiper-homocisteinemia. Nessa revisão, serão abordadas as condições que conduzem à hiper-homocisteinemia, tais como fatores genéticos e nutricionais, e os mecanismos pelos quais a hiper-homocisteinemia potencializa o desenvolvimento da aterosclerose. O presente trabalho foi desenvolvido por meio de revisão sistemática da literatura nacional e internacional pelo indexador MedLine/PubMed, utilizando os unitermos: homocisteína, cardiovascular, risco, aterosclerose, radicais livres.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Ross. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340(2) 115-26.

Lusis AJ. Atherosclerosis. Nature. 2000; 407(6801): 233-41.

Clarke R, Daly L, Robinson K, et ai. Hyperhomo­ cysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991; 324:1149-55.

Wilcken DEL, Dudman NPB. Homocystinuria and atherosclerosis. ln: Lusis AJ, Rotter Jl, Sparkes RS, editors. Molecular genetics of coronary artery disease; candidate genes and process in atherosclerosis. Monograms in human genetics. New York: Karger; 1992. p.311.

Gordon T, Garcia-Palmieri MR, Kagan A, Kannel WB, Schiffman J. Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. J Chronic Dis. 1974; 27(7-8):329-44.

Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann lntern Med. 1979; 90(1):85-91.

Mosher DF. Disorder s of blood coagulation. ln: Wyngaarden JB, Smith LH, Bennet JC, Cecil Murray­ Rust J, Leiper J, McAlister M, et ai. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine imethylaminohydrolase.

Nat Struct Biol. 2001; 8(8):679-83.

Malinow M. Hyperhomocysteinemia: a common and easily resersible risk factor for occlusive atherosclerosis. Circulation. 1990; 81(6):2004-6

Neves LB, Macedo DM, Lopes AC. Homocisteína. J Bras Patol Med Lab. 2004; 40(5):311-20.

Brasileiro RS. Homocisteína, ácido fálico, vitamina B, em adolescentes obesos de escola pública da cidade de São Paulo: estudo de caso-controle [tese]. São Paulo: Universidade Federal de São Paulo; 2004.

Carson NAJ, Neil DW. Metabolic abnormalities detected in a survey of mentally backward individuais in Northern lreland. Arch Dis Child. 1962; 37:505-13.

McCully, K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969; 56:111-28.

Eikelboom JW, Lonn E, Genest Jr J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a criticai review of the epidemiologic evidence. Ann lntern Med. 1999; 131(5):363-75.

Perez-de-Arce K, Foncea R, Leighton F. Reactive oxygen species mediates homocysteine-induced mitochondrial biogenesis in human endothelial cells: modulation by antioxidants. Biochem Biophys Res Commun. 2005; 338(2): 1103-9.

Baydas G, Ozer M, Yasar A, Koz ST, Tuzcu M. Melatonin prevents oxidative stress and inhibits reactive gliosis induced by hyperhomocysteinemia in rats. Biochemistry (Moscou). 2006; 71(Suppl 1):S91-5

Reutens S, Sachdev P Homocysteine in neuropsychiatric disorders of the elderly. lnt J Geriatr Psychiatry. 2002; 17:859-64.

Gauthier GM, Keevil JG, McBride PE. The association of homocysteine and coronary artery disease. Clin Cardiol. 2003; 26(12):563-8.

Venâncio LS, Burini RC, Yoshida WB. Hiper-homocis­ teinemia na doença arterial periférica. J Vasc Br. 2004; 3(1):31-7.

Eikelboom JW, Lonn E, Genest Jr J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a criticai review of the epidemiologic evidence. Ann lntern Med. 1999; 131(5):363-75.

Fowler B. Homocysteine: overview of biochemistry, molecular biology, and role in disease processes. Semin Vasc Med. 2005; 5(2):77-86.

Bydlowski SP, Magnanelli AC, Chamone DAF. Hiper­ Homocisteinemia e doenças vaso-oclusivas. Arq Bras Cardiol. 1998; 71(1):69-76.

Cabezas AM, Rodríguez JEFB. Metabolismo de la homocisteína y su relación con la aterosclerosis. Rev Cubana lnvest Biomed. 1999; 18(3):155-68.

Jaconsen DW. Homocysteine and vitamins in car­ diovascular disease. Clin Chem 1998; 44(8):1833-43

Frantzen F, Faaren AL, Alfheim 1, Nordhei AK. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem. 1998; 44(2):311-6.

Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem. 1995; 41(3): 340-2.

Duell PB, Malinow MR. Homocysteinemia and risk of atherosclerosis: a clinicai approach to evaluation and management. Endocrinologisty. 1998; 8:170-27.

Gravina-Taddei CF, Batlouni M, Sarteschi C, Saltar VT, Nívea AC, Salvarini MC, et ai. Hiper-Homocisteinemia como fator de risco para doença aterosclerótica coronariana em idosos. Arq Bras Cardiol. 2005; 85(3):166-73.

Jaconsen DW. Homocysteine and vitamins in car­ diovascular disease. Clin Chem. 1998; 44(8): 1833-43.

Kraus JP. Biochemistry and molecular genetics of cystathionine beta-synthase. deficiency. Eur J Pediatr. 1998; 157(2):S50-3.

McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis. 1975; 22(2):215-27 _

Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch

G. lntermediate homocystinuria: a thermolabile variant of methylene tetrahydrofolate reductase. Am J Hum Genet. 1988; 43(4):414-21.

Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998; 338(15): 1042-50.

McAndrew PE, Brandt JT, Pearl DK, Prior TW. The incidence of the gene for themolabile methylene tetrahydrofolate reductase in African Americans. Thromb Res. 1996; 83(2):195-8.

Wagner WE, Levine B. Folie acid and neural tube defects. Curr Concepts Nutr. 1993; 8:1-12.

Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, et ai. lncreased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscl Thromb Vasc Biol. 2003; 23(3):418-24.

Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Tolliet M, et ai. Endothelial dysfunction in a murine model of mild hyperhomocyst( e)inemia. J Clin lnvest. 2000; 106(4):483-91.

Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DO, et ai. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine b-synthasedeficient mice. Circ Res. 2001; 88(11):1203-9

Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999; 100(11):1161-8.

Faraci FM. Hyperhomocysteinemia: a million ways to lose contrai. Arterioscl Thromb Vasc Biol. 2003; 23(3):371-3

Pinto WJ, Areas MA, Reyes FGR. óxido nítrico e o sistema vascular: uma revisão. Acta Cient Biol Saúde. 2003; 5(1):47-61.

McAndrew PE, Brandt JT, Pearl DK, Prior TW. The incidence of the gene for themolabile methylene tetrahydrofolate reductase in African Americans. Thromb Res. 1996; 83(2):195-8.

Lentz, SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost. 2005; 3(8): 1646-54.

Dayal S, Brown KL, Weydert CJ, Oberley LW, Arning E, Bottiglieri T, et ai. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscl Thromb Vasc Biol. 2002; 22(12):1996-2002.

Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, et ai. lncreased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscl Thromb Vasc Biol. 2003; 23(3):418-24.

Guida-Cardoso SM, Pinto WJ, Ogo HS, Reyes FGR, Areas MA. Dietary fiber reduces lipid peroxidation and mean bloood pressure in hypercholesterolemic hamsters. Alimentaria. 2004; 4:31-34.

Ullrich V, Bachschmid M. Superoxide as a messenger of endothelial function. Biachem Biophys Res Commun. 2000; 278(1):1-8.

Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase: a Ca2+/ calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem. 1998; 273(40): 25804-8.

Patel KB, Stratford MR, Wardman P, Everett S A. Oxidation of tetrahydrobiopterin by biological radicais and scavenging. Free Radie Biol Med. 2002; 32(3):203-11.

Landmesser U, Dikalov 5, Price SR, McCann L, Fukai T, Holland SM , et ai. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin lnvest. 2003; 111(8): 1201-9.

Publicado

2009-12-31

Cómo citar

Pinto, W. de J., Areas, M. A., Marialva, J. E. de, Cardoso, S. M. G., & Pinto, E. G. (2009). Homocisteína e risco cardiovascular. Revista De Ciências Médicas, 18(5/6). Recuperado a partir de https://seer.sis.puc-campinas.edu.br/cienciasmedicas/article/view/625

Número

Sección

Revisão